What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-05-16 compared with 2021-11-15 · 61 added, 33 removed, 60 unchanged (61% of the section changed)

OTHER INFORMATION.

The following

exhibits are filed herewith:

The following exhibits are filed herewith:

Share Exchange Agreement, dated February 8, 2016 (1)

11 unchanged sentences

Collaboration Agreement with BioFirst dated July 24, 2017 (12)

Co-Development

Agreement with Rgene dated May 26, 2017 (13)

Co-Development Agreement with Rgene dated May 26, 2017 (13)

Employment Agreement with Dr.

19 unchanged sentences

And BioLite Japan K.K.

Amendment to the Collaboration Agreement dated December 29, 2015 +

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+

12 unchanged sentences

accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

(1) Incorporated

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 16, 2016.

(2) Incorporated

by reference to Exhibit 3.01 to the Company’s Form SB-2 filed on June 28, 2002

(3) Incorporated

by reference to Exhibit 3.02 to the Company’s Form SB-2, filed on June 28, 2002

(4) Incorporated

by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 28, 2016.

(5) Incorporated

by reference to Exhibit 3.4 to the Company’s Form S-1, filed on September 13, 2016.

(6) Incorporated

by reference to Exhibit 3.1 to the Company’s Form 8-K, filed on April 7, 2020

(7) Incorporated

by reference to Exhibit 4.1 the Company’s Current Report on Form 8-K, filed on April 24, 2020

(8) Incorporated

by reference to Exhibit 10.2 the Company’s Current Report on Form 8-K, filed on February 16, 2016.

(9) Incorporated

by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 9, 2016.

by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on January 12, 2017.

by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 22, 2017.

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 24, 2017.

by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on May 30, 2017.

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 24, 2020.

by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed April 14, 2020.

by reference to Exhibit 10.15 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K, filed May 15, 2020

by reference to Exhibit 14.1 to the Company’s Amendment No.1 to Form S-1, filed on November 14, 2016.

by reference to 21.1 to the Company’s Form S-1, filed on September 13, 2016.

by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K, filed March 16, 2021.

by reference to the Current Report on Form 8-K filed on November 5, 2020.

by reference to the Current Report on Form 8-K filed on June 8, 2021.

by reference to the Quarterly Report on Form 10-Q filed on May 10, 2021.

Incorporated by reference to the Current Report on Form 8-K filed on October 8, 2021.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

BioPharma, Inc.

November 15, 2021

Executive Officer

Incorporated by reference

to Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on January 12, 2017.

Incorporated by reference

to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 22, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 24, 2017.

Incorporated by reference

to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on May 30, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 24, 2020.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed April 14, 2020.

Incorporated by reference

to Exhibit 10.15 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference

to Exhibit 10.16 to the Company’s Annual Report on Form 10-K, filed May 15, 2020

Incorporated by reference

to Exhibit 14.1 to the Company’s Amendment No.1 to Form S-1, filed on November 14, 2016.

Incorporated by reference

to 21.1 to the Company’s Form S-1, filed on September 13, 2016.

Incorporated by reference

to Exhibit 10.9 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference

to Exhibit 10.17 to the Company’s Annual Report on Form 10-K, filed March 16, 2021.

Incorporated by reference

to the Current Report on Form 8-K filed on November 5, 2020.

Incorporated by reference

to the Current Report on Form 8-K filed on June 8, 2021.

Incorporated by reference

to the Quarterly Report on Form 10-Q filed on May 10, 2021.

Incorporated by reference

to the Current Report on Form 8-K filed on October 8, 2021.

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABVC BioPharma, Inc.

Chief Executive Officer

(Principal Executive Officer)

BioPharma, Inc.

November 15, 2021

Financial Officer

ABVC BioPharma, Inc.

/s/ Chihliang

Chief Financial Officer

(Principal Financial Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information